Eshelman Innovation Curation Program (Therapeutics Accelerator)
Offers translational awards at the University of North Carolina for therapeutic innovations in cancer, brain, and infection treatment.
Eshelman Innovation's Therapeutics Accelerator funds novel therapeutics in oncology, neuroscience, and infectious disease from discovery through preclinical and early development. The Innovation Curation Program is the core funding mechanism: a 5-stage process (Opportunity Mapping → Stakeholder Engagement → Event Summit → Joint RFP → Co-Creation/Investment) that partners UNC researchers with biopharma, VC, and external funders to co-create problem statements and issue Joint Requests for Proposals. The broader Therapeutics Accelerator has deployed >$30M since its founding with a $100M gift from Fred Eshelman in 2014. Eligibility is primarily restricted to UNC-Chapel Hill faculty, postdocs, and PhD/PharmD students, with limited extension to NC ecosystem partners for joint RFPs. No grants emitted (internal-only; specific RFP amounts not published in source).
No upcoming rounds verified. Cadence: Rolling.